Publication: First‐in‐man allopregnanolone use in super‐refractory status epilepticus
Loading...
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley and Sons Inc.
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Vaitkevicius, Henrikas, Aatif M. Husain, Eric S. Rosenthal, Jonathan Rosand, Wendell Bobb, Kiran Reddy, Michael A. Rogawski, and Andrew J. Cole. 2017. “First‐in‐man allopregnanolone use in super‐refractory status epilepticus.” Annals of Clinical and Translational Neurology 4 (6): 411-414. doi:10.1002/acn3.408. http://dx.doi.org/10.1002/acn3.408.
Abstract
Abstract Super‐refractory status epilepticus (SRSE) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that positively modulates synaptic and extrasynaptic GABAA receptors, has been proposed as a novel treatment. We describe the first two patients with SRSE who were each successfully treated with a 120‐h continuous infusion of allopregnanolone. Both patients recovered from prolonged SRSE with good cognitive outcomes.
Description
Other Available Sources
Research Data
Keywords
Brief Communication
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service